What is Alnylam Pharmaceuticals, Inc.'s Shariah compliance score?

Alnylam Pharmaceuticals, Inc. (ALNY) has a Shariah compliance score of 73/100 (Grade: B+, Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Alnylam Pharmaceuticals, Inc. pass AAOIFI screening?

Alnylam Pharmaceuticals, Inc. (ALNY) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (ALNY: 4.0%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for Alnylam Pharmaceuticals, Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Alnylam Pharmaceuticals, Inc. (ALNY) using the latest financial data.

Where can I screen Alnylam Pharmaceuticals, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Alnylam Pharmaceuticals, Inc. (ALNY) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about ALNY's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

ALNY: Is Alnylam Pharmaceuticals, Inc. Halal?

Alnylam Pharmaceuticals, Inc.

NASDAQHealthcareUS

$228.65

+0.67%

Market Cap: 30.6B

Compliance Status

Halal

Screened on Aug 31, 2026 · AAOIFI Standard 21

B+

Good

73Score

Is Alnylam Pharmaceuticals, Inc. (ALNY) halal? Halal. Based on AAOIFI screening, Alnylam Pharmaceuticals, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 73/100 (Grade: B+).

Quote this verdict

HalalScreener rates Alnylam Pharmaceuticals, Inc. (ALNY) Halal, 73/100, grade B+ under AAOIFI Standard 21, screened Aug 31, 2026. Source: https://halalscreener.app/en/stock/ALNY

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

4.0% of 30.0% limit

What this means for you

You can own ALNY

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened ALNY's prohibited income, but the exact share you would need to purify is part of Pro.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 31, 2026

Compliance History

Halalnow
since Aug 2026
Not Halal
until the change above
Halal
until the change above

Tracked since Jun 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track ALNY and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. (ALNY) halal to invest in?

Based on AAOIFI Standard 21 screening, Alnylam Pharmaceuticals, Inc. (ALNY) is rated Halal with a compliance grade of B+ (Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Alnylam Pharmaceuticals, Inc. get a B+ compliance rating?

Alnylam Pharmaceuticals, Inc. (ALNY) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 4.0% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Alnylam Pharmaceuticals, Inc.'s Shariah verdict?

Alnylam Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Alnylam Pharmaceuticals, Inc. re-screened for Shariah compliance?

Alnylam Pharmaceuticals, Inc. (ALNY) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 31, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.